SCHEDULE: Opaleye Management Discloses Stake in Q32 Bio

Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, disclosing a beneficial ownership of 5.49% in Q32 Bio Inc.

Summary

• Opaleye Management Inc., Opaleye L.P., and James Silverman (collectively, the Reporting Persons) have filed an amendment to their Schedule 13G.
• The filing indicates a beneficial ownership of 931,000 shares of Q32 Bio Inc. common stock.
• This represents 5.49% of the outstanding shares, based on 16,956,415 shares reported as of May 1, 2026.
• Opaleye L.P. directly holds the shares, while Opaleye Management Inc. acts as the investment adviser, and James Silverman is the controlling person of the Adviser.
• The filing states that the securities were not acquired or held for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of beneficial ownership without providing performance metrics or strategic insights into Q32 Bio Inc.

Positives

• Disclosure of a significant ownership stake (5.49%) by a management entity and its controlling person in Q32 Bio Inc.
• The filing is an amendment, suggesting ongoing management and potential strategic interest in the company.

Negatives

• The filing does not contain any financial performance data or operational updates for Q32 Bio Inc., limiting the assessment of the company's health.
• The nature of the investment (passive vs. active) is not detailed beyond the standard certification.

Risks

• The filing does not explicitly mention any risks associated with Q32 Bio Inc. or the investment itself.
• Potential for increased scrutiny from regulators or other investors due to the disclosure of a substantial stake.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Q32 Bio Inc.'s future performance.

Management Comments

• "The filing of this statement shall not be construed as an admission that any Reporting Person is the beneficial owner of any securities covered by this statement for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or otherwise."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes. However, the involvement of an investment adviser and its controlling person suggests a potentially more active, albeit not control-oriented, interest in Q32 Bio Inc. This type of filing is common in the biotechnology sector where significant stakes can be acquired by specialized investment firms.

Stakeholder Impact

• Shareholders: The disclosure may signal increased institutional interest in Q32 Bio Inc., potentially influencing market perception.
• Management of Q32 Bio Inc.: May be aware of increased scrutiny or potential for engagement from Opaleye Management.

Next Steps

• The Reporting Persons may file amendments to this Schedule 13G if their beneficial ownership changes.
• Q32 Bio Inc. will continue its operations as disclosed in its other SEC filings.

Key Dates

Keywords

Q32 Bio Inc., Schedule 13G, Opaleye Management, Opaleye L.P., James Silverman, Beneficial Ownership, SEC Filing, Investment Management